Emyria Ltd (AU:EMD)
ASX:EMD
Want to see AU:EMD full AI Analyst Report?
Top Page
Emyria Ltd
(Sydney:EMD)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.05
▼(-18.33% Downside)
Action:ReiteratedDate:04/21/26
The score is held down primarily by weak financial performance (declining revenue, negative margins, and cash flow deficits). Technicals are comparatively better, with price above major moving averages and positive momentum indicators, but valuation remains pressured due to loss-making earnings (negative P/E).
Positive Factors
Low leverage / manageable debt
A low debt-to-equity ratio (0.12) reduces interest burden and financial distress risk, giving management flexibility to fund clinic operations or research programs. This balance sheet conservatism supports multi-month resiliency and lowers refinancing pressure while pursuing strategic growth.
Negative Factors
Declining revenue and negative margins
A meaningful revenue decline combined with persistent negative gross and operating margins indicates structural profitability issues. Sustained losses erode reinvestment capacity, limit strategic initiatives, and imply the current business mix and cost base are not delivering durable unit economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / manageable debt
A low debt-to-equity ratio (0.12) reduces interest burden and financial distress risk, giving management flexibility to fund clinic operations or research programs. This balance sheet conservatism supports multi-month resiliency and lowers refinancing pressure while pursuing strategic growth.
Read all positive factors
Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$41.13M
Dividend YieldN/A
Average Volume (3M)4.06M
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue Growth-36.68%
EPS Growth79.41%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,556,500
10 Day Avg. Volume2,903,931
30 Day Avg. Volume4,056,978
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.37
Price to Sales (P/S)9.01
P/FCF Ratio-4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$5.90M
Emyria Ltd Business Overview & Revenue Model
Company Description
Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops cannabinoid-based medicines, as well as MDMA drug discovery program. Its drug development program includes EMD...
How the Company Makes Money
Emyria’s revenue model is based on a combination of (1) clinical services income and (2) research-related income. (1) Clinical services income is generated through patient care delivered by Emyria’s specialist mental health clinics (e.g., consulta...
Emyria Ltd Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.18M | 1.39M | 2.20M | 1.59M | 1.82M | 1.98M |
| Gross Profit | -1.23M | 24.48K | -167.55K | -3.32M | -4.41M | -1.58M |
| EBITDA | -4.27M | -2.39M | -13.03M | -6.69M | -8.03M | -4.49M |
| Net Income | -4.55M | -3.14M | -11.46M | -5.13M | -7.33M | -4.91M |
Balance Sheet | ||||||
| Total Assets | 13.66M | 6.62M | 5.43M | 10.16M | 8.25M | 9.06M |
| Cash, Cash Equivalents and Short-Term Investments | 10.50M | 3.57M | 1.57M | 2.73M | 3.88M | 6.53M |
| Total Debt | 1.06M | 613.50K | 1.72M | 1.27M | 632.70K | 949.70K |
| Total Liabilities | 1.56M | 1.31M | 3.00M | 3.37M | 1.93M | 1.88M |
| Stockholders Equity | 12.10M | 5.31M | 2.43M | 6.79M | 6.32M | 7.18M |
Cash Flow | ||||||
| Free Cash Flow | -3.77M | -2.72M | -4.44M | -7.01M | -7.46M | -4.60M |
| Operating Cash Flow | -3.72M | -2.70M | -4.28M | -3.77M | -5.43M | -3.94M |
| Investing Cash Flow | -15.56K | 81.07K | -1.38M | -3.23M | -2.03M | -661.39K |
| Financing Cash Flow | 12.68M | 4.63M | 4.50M | 5.86M | 4.81M | 7.44M |
Emyria Ltd Technical Analysis
Neutral
0.06
Price Trends
0.05
Positive
0.05
Negative
0.05
Negative
Market Momentum
<0.01
Negative
56.26
Neutral
80.95
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EMD, the sentiment is Neutral. The current price of 0.06 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.05, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.26 is Neutral, neither overbought nor oversold. The STOCH value of 80.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:EMD.
Emyria Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$20.82M | -7.11 | -19.01% | ― | 6.77% | -8.45% | |
49 Neutral | AU$20.99M | 3.95 | 7.57% | ― | 28.91% | -1050.00% | |
47 Neutral | AU$41.13M | -4.21 | -52.26% | ― | -36.68% | 79.41% | |
43 Neutral | AU$69.51M | -6.64 | -59.96% | ― | ― | ― | |
43 Neutral | AU$31.35M | -3.13 | -1009.84% | ― | 25.98% | 22.10% |
* Healthcare Sector Average
AU:EMD
Emyria Ltd
0.05
0.02
92.31%
AU:RHT
Resonance Health Ltd
0.04
<0.01
10.00%
AU:SHG
Singular Health Group Ltd
0.22
-0.05
-16.98%
AU:IME
ImExHS Limited
0.39
0.04
13.24%
AU:PCK
PainChek Ltd
0.15
-0.20
-57.14%
Emyria Ltd Corporate Events
Emyria outlines high-risk, early-stage push into psychedelic mental health therapies
Apr 20, 2026
Emyria used its presentation at the Ignite Investment Summit in Singapore to outline its strategy in advanced mental health therapies based on MDMA, psilocybin and related compounds. The company emphasised that these products are still undergoing ...
Emyria moves to digital distribution for upcoming shareholder meeting
Mar 30, 2026
Emyria has called a general meeting of shareholders to be held in Perth on 1 May 2026, with investors able to attend in person or vote via proxy through multiple electronic and physical channels. In line with Australian corporate law and a broader...
Emyria calls extraordinary meeting to ratify major share placement and manager options
Mar 30, 2026
Emyria Limited has called an extraordinary general meeting for 1 May 2026 in West Perth, setting a record date of 29 April 2026 for shareholders eligible to vote. The meeting follows recent capital-raising activity and will allow investors to revi...
Emyria on Track to Launch First Victorian Empax Clinic in Q2 2026
Mar 23, 2026
Emyria says its first Empax clinic in Victoria remains on schedule to begin treating patients in the second quarter of 2026, marking a key step in its national rollout of reimbursable mental health services. The clinic will expand the company̵...
Emyria to Showcase Mental Health Treatment Strategy at NWR Virtual Healthcare Conference
Mar 23, 2026
Emyria Limited, a healthcare innovator focused on mental health and neurological disorders, leverages its Emyria Healthcare clinics and real-world data platform to evaluate emerging therapies, including psychedelic-assisted treatments, and to adva...
Emyria posts record half-year as payer support fuels national Empax clinic rollout
Feb 26, 2026
Emyria reported a record half-year to 31 December 2025, with revenue rising 136% to $1.55 million, driven by the expansion of its Empax mental health clinic network and the start of insurer-funded treatments in multiple states. The company remains...
Emyria lifts revenue but posts wider half-year loss
Feb 26, 2026
Emyria Limited reported a strong increase in revenue from customer sales and clinical services for the half-year ended 31 December 2025, with income rising 136% to $1.55 million compared with the prior corresponding period. Despite this top-line g...
Emyria Seeks Quotation for Additional Ordinary Shares on ASX
Feb 6, 2026
Emyria Ltd has applied to the ASX for quotation of 2,834 new fully paid ordinary shares under code EMD, following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities slightly exp...
Emyria underscores cautious path for psychedelic-assisted therapies
Feb 4, 2026
The company outlines its strategy to expand access to psychedelic-assisted psychotherapy, emphasizing rigorous clinical oversight and safety considerations, while acknowledging risks associated with MDMA and psilocybin compounds and the absence of...
Emyria Applies for Quotation of Additional Ordinary Shares on ASX
Feb 3, 2026
Emyria Ltd has applied to the ASX for quotation of 36,250 new fully paid ordinary shares (code: EMD), which were issued on 30 January 2026 following the exercise or conversion of existing options or other convertible securities. The modest increas...
Emyria Schedules Investor Webinar to Outline Quarterly Progress and Outlook
Jan 29, 2026
Emyria Limited has invited investors to a quarterly webinar on 3 February 2026, where Executive Chairman Greg Hutchinson and COO Mary-Ann Rennie will present the company’s December quarter activities and outline the outlook for the coming qu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.